Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCN NASDAQ:ENSC NASDAQ:HOOK NASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.10-2.8%$2.55$1.03▼$8.48$13.51M1.84.21 million shs13,698 shsENSCEnsysce Biosciences$0.35-8.4%$0.49$0.30▼$2.75$3.23M0.875.24 million shs2.59 million shsHOOKHOOKIPA Pharma$1.18$1.11$0.81▼$1.77$14.55M0.8411,125 shs1,676 shsPASGPassage Bio$4.66+5.9%$7.57$3.93▼$20.00$14.96M1.3878,011 shs103,051 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+2.90%-2.15%+9.62%+172.65%-2.74%ENSCEnsysce Biosciences+9.08%-1.80%-17.76%-13.36%-82.40%HOOKHOOKIPA Pharma0.00%-0.42%+3.51%+11.32%-9.23%PASGPassage Bio+4.51%-11.47%-55.51%-52.79%-33.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.10-2.8%$2.55$1.03▼$8.48$13.51M1.84.21 million shs13,698 shsENSCEnsysce Biosciences$0.35-8.4%$0.49$0.30▼$2.75$3.23M0.875.24 million shs2.59 million shsHOOKHOOKIPA Pharma$1.18$1.11$0.81▼$1.77$14.55M0.8411,125 shs1,676 shsPASGPassage Bio$4.66+5.9%$7.57$3.93▼$20.00$14.96M1.3878,011 shs103,051 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+2.90%-2.15%+9.62%+172.65%-2.74%ENSCEnsysce Biosciences+9.08%-1.80%-17.76%-13.36%-82.40%HOOKHOOKIPA Pharma0.00%-0.42%+3.51%+11.32%-9.23%PASGPassage Bio+4.51%-11.47%-55.51%-52.79%-33.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 1.00SellN/AN/AENSCEnsysce Biosciences 1.00SellN/AN/AHOOKHOOKIPA Pharma 0.00N/AN/AN/APASGPassage Bio 2.14Hold$13.25184.33% UpsideCurrent Analyst Ratings BreakdownLatest ENSC, HOOK, PASG, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ENSCEnsysce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.004/21/2026PASGPassage Bio TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/21/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$32.00 ➝ $8.004/20/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageReduce4/20/2026PASGPassage Bio Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/31/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.003/27/2026PASGPassage Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.07M6.48N/AN/A$2.31 per share1.34ENSCEnsysce Biosciences$5.07M0.64N/AN/A$0.63 per share0.56HOOKHOOKIPA Pharma$9.35M1.56N/AN/A$4.25 per share0.28PASGPassage BioN/AN/AN/AN/A$5.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$3.53M-$1.16N/AN/AN/A-170.11%-39.23%-35.62%5/15/2026 (Estimated)ENSCEnsysce Biosciences-$10.18M-$4.22N/AN/AN/A-200.87%-426.62%-195.53%5/12/2026 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%N/APASGPassage Bio-$45.52M-$14.48N/AN/AN/AN/A-135.04%-60.37%5/12/2026 (Estimated)Latest ENSC, HOOK, PASG, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026N/ACYCNCyclerion Therapeutics-$17.20N/AN/AN/A$0.88 millionN/A5/12/2026Q1 2026ENSCEnsysce Biosciences-$0.73N/AN/AN/A$1.90 millionN/A5/12/2026Q1 2026PASGPassage Bio-$2.70-$2.36+$0.34-$2.36N/AN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 million3/30/2026Q4 2025ENSCEnsysce Biosciences-$1.26-$0.75+$0.51-$0.75$0.50 million$1.88 million3/3/2026Q4 2025PASGPassage Bio-$2.19-$4.08-$1.89-$4.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A5.155.15ENSCEnsysce BiosciencesN/A1.591.59HOOKHOOKIPA PharmaN/A3.613.61PASGPassage BioN/A2.072.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%ENSCEnsysce Biosciences5.63%HOOKHOOKIPA Pharma63.88%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%ENSCEnsysce Biosciences2.80%HOOKHOOKIPA Pharma3.30%PASGPassage Bio4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataENSCEnsysce Biosciences109.28 million9.02 millionNot OptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionablePASGPassage Bio1303.21 million3.05 millionNo DataENSC, HOOK, PASG, and CYCN HeadlinesRecent News About These CompaniesPassage Bio (PASG) to Release Earnings on TuesdayMay 10 at 3:34 AM | americanbankingnews.comPassage Bio (NASDAQ:PASG) Raised to "Sell" at Wall Street ZenMay 3, 2026 | americanbankingnews.comPassage Bio (PASG) price target decreased by 62.83% to 11.63April 28, 2026 | msn.comTD Cowen downgrades Passage Bio (PASG)April 23, 2026 | msn.comPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesApril 20, 2026 | globenewswire.comPassage Bio (PASG) Gets a Buy from Chardan CapitalApril 8, 2026 | theglobeandmail.comOppenheimer initiates coverage of Passage Bio (PASG) with outperform recommendationApril 1, 2026 | msn.comPassage Bio (PASG) price target decreased by 22.22% to 31.42March 28, 2026 | msn.comPassage Bio advances frontotemporal dementia trial and reports 2025 resultsMarch 10, 2026 | msn.comPassage Bio Ends Hopewell Lab Lease, Extends Cash RunwayMarch 10, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG)March 8, 2026 | theglobeandmail.comPassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business HighlightsMarch 3, 2026 | globenewswire.comPassage Bio management to present at two healthcare conferencesFebruary 24, 2026 | msn.comPassage Bio to Participate in Upcoming Investor ConferencesFebruary 19, 2026 | globenewswire.comPassage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in StockJanuary 13, 2026 | insidertrades.comFinancial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)December 7, 2025 | defenseworld.netDPassage Bio (PASG) price target increased by 21.85% to 40.39December 7, 2025 | msn.comPassage Bio initiated with a Buy at Lucid CapitalNovember 24, 2025 | msn.comPassage Bio (PASG) Price Target Decreased by 45.15% to 33.15November 17, 2025 | msn.comPassage Bio reports Q3 EPS ($2.44), consensus ($2.97)November 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENSC, HOOK, PASG, and CYCN Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.10 -0.09 (-2.82%) As of 11:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Ensysce Biosciences NASDAQ:ENSC$0.35 -0.03 (-8.38%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.HOOKIPA Pharma NASDAQ:HOOK$1.18 0.00 (0.00%) As of 09:55 AM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Passage Bio NASDAQ:PASG$4.66 +0.26 (+5.91%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
